



We turn science into medicine

Our appreciation for, and understanding of, the power of the human immune system gives us a unique perspective on how to respond to the constant challenges of oncology drug development. We use our expertise to produce innovative antibody-based therapeutics that have the potential to transform cancer treatment.


Our pipeline of antibody therapeutics includes products in clinical development, and in-house and partnered pre-clinical programs.

Our proprietary antibody platforms




DuoBody® for the generation of bispecific antibodies

- Innovative platform generates bispecific antibodies capable of dual targeting with minimal engineering
- Built on our in-depth understanding of the naturally occurring process of Fab-arm exchange to generate stable bispecific antibodies while retaining immunoglobulin G1 (IgG1) structure and function




HexaBody® for potentiated antibodies

- Broadly applicable technology that builds on natural antibody biology
- HexaBody® technology induces formation of hexamers (clusters of six) by antibodies after they bind to their targets on the cell surface. This potentially enhances the natural killing ability of antibodies while retaining their regular structure and specificity



DuoHexaBody® for the generation of bispecific antibodies with enhanced potency

- Combines the dual targeting of our DuoBody® technology with the enhanced potency of our HexaBody® technology to generate bispecific antibodies with target-mediated enhanced hexamerization
- Enhances CDC of target cells. Clustering of target receptors by the antibody hexamer can lead to outside-in signaling and to apoptosis, for example



HexElect® for dual-targeting antibodies with enhanced potency and selectivity

- Technology combines two HexaBody® molecules designed to effectively and selectively hit only those cells that express both targets. This is achieved by making the activity of the complexes dependent on their binding to two different targets on the same cell
- Two co-dependently acting HexaBody® molecules effectively and selectively target only those cells that express both targets

For additional information, [click here](#).

Innovative clinical and pre-clinical pipeline

Our product pipeline consists of 23 antibodies in clinical development, including three marketed products*, as well as ~20 in-house and partnered pre-clinical programs

Product	Clinical trial or disease indication	Development phase				
		Pre-clinical	I	I/II	II	III
Tisotumab vedotin Partner: Seagen Inc.†	innovaTV 204: Second- or third-line treatment for recurrent or metastatic cervical cancer (NCT03438396)					
	innovaTV 205: Safety and efficacy of tisotumab vedotin monotherapy and in combination with other cancer agents in patients with cervical cancer (NCT03786081)					
	innovaTV 206: Previously treated locally advanced or metastatic solid tumors in Japanese patients (NCT03913741)					
	innovaTV 207: Previously treated relapsed, locally advanced or metastatic solid tumors (NCT03485209)					
	innovaTV 208: Platinum-resistant ovarian cancer (NCT03657043)					
Epcoritamab DuoBody® CD3xCD20 Partner: AbbVie Inc.‡	Monotherapy in relapsed, progressive or refractory B-cell non-Hodgkin lymphoma (B-NHL) (NCT03625037)					
	Monotherapy in relapsed/refractory chronic lymphocytic leukemia (CLL) (NCT04623541)					
	Monotherapy in Japanese patients with relapsed/refractory B-NHL (NCT04542824)					
	Monotherapy versus standard of care in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) (NCT04628494)					
GEN1046 DuoBody® PD-L1x4-1BB Partner: BioNTech§	Relapsed or refractory, advanced and/or metastatic solid tumors (NCT03917381)					
GEN1042 DuoBody® CD40x4-1BB Partner: BioNTech§	Safety trial in malignant solid tumors (NCT04083599)					
GEN1029 HexaBody® DR5/DR5	Advanced and/or metastatic solid tumors (NCT03576131)					
GEN1044 DuoBody® CD3x5T4 Partner: AbbVie Inc.‡	Safety trial in malignant solid tumors (NCT04424641)					
GEN3014 HexaBody® CD38	Safety trial in hematologic malignancies					
GEN3009 DuoHexaBody® CD37 Partner: AbbVie Inc.‡	Safety trial in relapsed/refractory B-NHL (NCT04358458)					

* Out-licensed products marketed by partner.

† Genmab in 50:50 partnership with Seagen Inc.

‡ Genmab in 50:50 partnership with AbbVie Inc.

§ Genmab in 50:50 partnership with BioNTech.

Genmab A/S and its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; HuMax; DuoBody; HexaBody; DuoHexaBody and HexElect.



About Genmab

Genmab is a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics.

The company is the creator of three approved therapies that are marketed by partners, including DARZALEX® (daratumumab), marketed by Janssen.

Genmab has a broad clinical and pre-clinical pipeline and a number of proprietary next generation antibody technologies.

Visit www.genmab.com for details.

